Statement Of Cash Flows [Abstract]

BerGenBio - Filing #2615544

Concept As at
2021-12-31
2021-01-01 to
2021-12-31
As at
2020-12-31
2020-01-01 to
2020-12-31
As at
2019-12-31
Statement of cash flows [abstract]
Cash flows from (used in) operating activities [abstract]
Cash flows from (used in) operating activities
303,340,000 NOK
234,290,000 NOK
Cash flows from (used in) investing activities [abstract]
Purchase of property, plant and equipment, classified as investing activities
67,000 NOK
Interest received, classified as investing activities
3,130,000 NOK
3,614,000 NOK
Cash flows from (used in) investing activities
3,130,000 NOK
3,548,000 NOK
Cash flows from (used in) financing activities [abstract]
Proceeds from issuing shares
16,629,000 NOK
740,852,000 NOK
Payments of lease liabilities, classified as financing activities
565,000 NOK
585,000 NOK
Cash flows from (used in) financing activities
15,995,000 NOK
699,507,000 NOK
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes
284,216,000 NOK
468,765,000 NOK
Effect of exchange rate changes on cash and cash equivalents [abstract]
Effect of exchange rate changes on cash and cash equivalents
779,000 NOK
710,000 NOK
Cash and cash equivalents
436,646,000 NOK
721,641,000 NOK
253,586,000 NOK

Talk to a Data Expert

Have a question? We'll get back to you promptly.